2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't

2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't

Exelixis (NASDAQ: EXEL) is without question one of the hottest biotech stocks on the market. We're talking about a stock that has more than tripled in value in just the last 12 months and has soared over 70% so far this year. Exelixis is, simply put, a fantastic growth stock.

But Wall Street thinks Incyte (NASDAQ: INCY) is an even better growth stock. Analysts project faster earnings growth over the next few years for Incyte and think the stock price will increase more in the next year than Exelixis' share price will. 

Is Wall Street right that Incyte is a better growth stock than Exelixis? Here are two reasons why the answer is "yes" -- and one why the experts could be wrong.

Continue reading

Source: Fool.com